OTC Markets OTCPK - Delayed Quote USD

Ascletis Pharma Inc. (ASCLF)

Compare
0.1517 0.0000 (0.00%)
At close: September 16 at 4:00 PM EDT
Loading Chart for ASCLF
DELL
  • Previous Close 0.0000
  • Open 0.2023
  • Bid 0.0915 x --
  • Ask 0.1715 x --
  • Day's Range 0.2023 - 0.2023
  • 52 Week Range 0.1402 - 0.2687
  • Volume 800
  • Avg. Volume 96
  • Market Cap (intraday) 151.183M
  • Beta (5Y Monthly) 0.68
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0300
  • Earnings Date Aug 30, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.

www.ascletis.com

219

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ASCLF

View More
Ascletis Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity

Ascletis Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity
Gannex Announces Poster Presentation of Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024

Gannex Announces Poster Presentation of Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024
Ascletis Announces Strategic Decisions on FXR agonist ASC42

Ascletis Announces Strategic Decisions on FXR agonist ASC42
Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting

Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting
Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne

Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis

Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis
Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne

Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
Ascletis Announces Poster Presentations at AASLD Annual Meeting 2023 Including a Late-Breaking Abstract of Interim Results from Phase IIb Expansion Cohort of ASC22 for Functional Cure of CHB

Ascletis Announces Poster Presentations at AASLD Annual Meeting 2023 Including a Late-Breaking Abstract of Interim Results from Phase IIb Expansion Cohort of ASC22 for Functional Cure of CHB

Dr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023

Gannex Published Phase I Data of ASC42, a Novel Farnesoid X Receptor Agonist on the Journal Drugs in R&D
View More

Performance Overview: ASCLF

Trailing total returns as of 9/17/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ASCLF
9.81%
HANG SENG INDEX
3.59%

1-Year Return

ASCLF
36.23%
HANG SENG INDEX
2.88%

3-Year Return

ASCLF
4,793.55%
HANG SENG INDEX
28.41%

5-Year Return

ASCLF
74.72%
HANG SENG INDEX
34.82%

Compare To: ASCLF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ASCLF

View More

Valuation Measures

Annual
As of 9/16/2024

  • Market Cap

    131.63M

  • Enterprise Value

    -191.29M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    110.81

  • Price/Book (mrq)

    0.46

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -10.18%

  • Return on Equity (ttm)

    -10.89%

  • Revenue (ttm)

    10.09M

  • Net Income Avi to Common (ttm)

    -258.47M

  • Diluted EPS (ttm)

    -0.0300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.09B

  • Total Debt/Equity (mrq)

    0.41%

  • Levered Free Cash Flow (ttm)

    -223.21M

View More

Company Insights: ASCLF

People Also Watch